Pro-Pharmaceuticals, Inc. (PRWP.OB) Announces Collaboration with Numoda to Increase DAVANAT’s Speed-to-Market
Pro-Pharmaceuticals, Inc. is engaged in the discovery, development and commercialization of therapeutics that target Galectin receptors for the advanced treatment of cancer. Today, Pro-Pharmaceuticals took a major step with the announcement they have collaborated with Numoda to manage the Phase III clinical trial of DAVANAT®. The combination of Pro-Pharmaceuticals and Numoda appears to be a winning one. DAVANAT is Pro-Pharmaceuticals’ lead product candidate and has excelled with the 100 cancer patients it was tested on. As for Numoda, the company is regarded as the world's most innovative and complete technology solutions provider in the life sciences industry. When asked what…